TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1500630

Group type: EXPERIMENTAL
Intervention: Peanut immunotherapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 6869487

Group type: EXPERIMENTAL
Intervention: Finger spreader
Number of subjects: 12

Group type: COMPARATOR
Intervention: Volar resting splint
Number of subjects: 12

Group type: COMPARATOR
Intervention: No device
Number of subjects: 12

Group type: COMPARATOR
Intervention: Firm cone
Number of subjects: 12
Study: 31881986

Group type: EXPERIMENTAL
Intervention: Fortified bread with 500 IU/100 g
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fortified bread with 1000 IU/100 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: Plain bread (control group)
Number of subjects: 90
Study: 29376774

Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Exercise (HICE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low Volume High-Intensity Interval Exercise (HIIE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 12
Study: 26764332

Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE) 2.56 g/d for 90 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24912844

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 201
Study: 22186135

Group type: EXPERIMENTAL
Intervention: TORCH (Treatment of Resistant Command Hallucinations)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined treatments
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 43
Study: 21293762

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 18065582

Group type: EXPERIMENTAL
Intervention: Atwater factors and related food energy conversion factors
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Modified Atwater factors
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Various factorial and empirical systems for calculating food energy
Number of subjects: 27
Study: 16237776

Group type: EXPERIMENTAL
Intervention: Perioperative parenteral nutrition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no parenteral nutrition)
Number of subjects: 32
Study: 12401582

Group type: EXPERIMENTAL
Intervention: 0.7% halothane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.5 micro g/kg IV fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1.5% lidocaine plus 0.35 mg/kg IV propofol
Number of subjects: 20
Study: 10343983

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7998062

Group type: EXPERIMENTAL
Intervention: Filtration of apheresis platelets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filtration of pooled platelets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filtration of CPDA-1 packed red cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filtration of Adsol packed red cells
Number of subjects: 0
Study: 2281802

Group type: EXPERIMENTAL
Intervention: Bright morning light (0600 to 0800)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bright evening light (2000 to 2200)
Number of subjects: 7
Study: 6809796

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Traditional process-oriented interpersonal group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy in an individual format
Number of subjects: 44
Study: 31355514

Group type: EXPERIMENTAL
Intervention: IL-Purified Protein Derivative (PPD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: IL-Vitamin D3
Number of subjects: 45
Study: 30081960

Group type: EXPERIMENTAL
Intervention: 60 min interactive session discussing STI and HIV education, risk mitigation, and effective partner notification strategies.
Number of subjects: 30
Study: 26814246

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High Dose (0.375% ropivacaine, perineural additives)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medium Dose (0.2% ropivacaine, perineural additives)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low Dose (0.1% ropivacaine, perineural additives)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High Dose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low Dose
Number of subjects: 80
Study: 25043834

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid plus pre-existing trainings
Number of subjects: 2543

Group type: COMPARATOR
Intervention: Pre-existing trainings only
Number of subjects: 2543
Study: 22242932

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2290
Study: 19057896

Group type: EXPERIMENTAL
Intervention: 25% nitrous oxide inhalation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air plus oxygen inhalation (control)
Number of subjects: 30
Study: 17463391

Group type: EXPERIMENTAL
Intervention: 20-minute one-on-one HIV/STD behavioral skill-building intervention
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: 200-minute group HIV/STD behavioral skill-building intervention
Number of subjects: 564

Group type: COMPARATOR
Intervention: 200-minute health intervention control group
Number of subjects: 564
Study: 16860171

Group type: COMPARATOR
Intervention: 20 mg/d olanzapine for 20 days (group A, n=12)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 30 mg/d for 10 days followed by 40 mg/d for 10 days (group B, n=11)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 40 mg/d for 20 days (group C, n=14)
Number of subjects: 37
Study: 14680736

Group type: EXPERIMENTAL
Intervention: Active (univentricular) pacing in long QRS group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inactive (ventricular inhibited) pacing in short QRS group
Number of subjects: 86
Study: 11013281

Group type: EXPERIMENTAL
Intervention: Teniposide with WBRT (10 fractions of 3 Gy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Teniposide alone
Number of subjects: 120
Study: 8840346

Group type: EXPERIMENTAL
Intervention: ipsapirone 10 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ipsapirone 20 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 1735848

Group type: EXPERIMENTAL
Intervention: Surfactant (Exosurf Neonatal)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 23
Study: 6547988

Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination therapy with cimetidine and pirenzepine (800 mg cimetidine and 100 mg pirenzepine daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (pre-treatment levels)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (serum calcium and phosphate levels)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (alkaline phosphatase activity)
Number of subjects: 24
Study: 30930051

Group type: EXPERIMENTAL
Intervention: Progressive resistance training performed twice a week for 10 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group continued their usual activities
Number of subjects: 16
Study: 30480666

Group type: EXPERIMENTAL
Intervention: Analysis of co-occurrence frequencies via relative frequency analysis and observed-expected frequency ratio
Number of subjects: 5364781

Group type: EXPERIMENTAL
Intervention: EHR prevalences
Number of subjects: 5364781
Study: 28728767

Group type: EXPERIMENTAL
Intervention: Temporal artery thermometer (TAT)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Oral thermometer
Number of subjects: 298

Group type: COMPARATOR
Intervention: Axillary thermometer
Number of subjects: 298
Study: 26708233

Group type: EXPERIMENTAL
Intervention: Trained resident coaches
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untrained resident coaches
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All students
Number of subjects: 14
Study: 24506405

Group type: EXPERIMENTAL
Intervention: Low-fat diet with antioxidant supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (low-fat diet)
Number of subjects: 9
Study: 21925636

Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling
Number of subjects: 597

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 597
Study: 18434976

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 microg once daily)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Number of subjects: 983
Study: 16177585

Group type: EXPERIMENTAL
Intervention: Internet-based educational intervention using cellular phone and Internet for blood glucose monitoring
Number of subjects: 42
Study: 13678870

Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily)
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Candesartan and Placebo
Number of subjects: 2028
Study: 10809018

Group type: EXPERIMENTAL
Intervention: HAART plus rIL-2
Number of subjects: 14

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 14
Study: 9010562

Group type: EXPERIMENTAL
Intervention: specific hyposensitization
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 1900443

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 35
Study: 6221388

Group type: EXPERIMENTAL
Intervention: Cefoperazone (16 micrograms/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cefamandole (16 micrograms/ml) and/or Tobramycin (4 micrograms/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cefamandole-tobramycin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 120
Study: 31277180

Group type: EXPERIMENTAL
Intervention: M-DEPTH (evidence-based stepped care treatment model)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: M-DEPTH
Number of subjects: 400
Study: 29216730

Group type: EXPERIMENTAL
Intervention: Standard therapeutic methods aimed at the temporomandibular joint
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Therapy aimed at cervical muscles only
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Complex rehabilitation (combination of relaxing and stretching exercises of cervical muscles with standard therapy for masticatory muscles)
Number of subjects: 98
Study: 25738784

Group type: EXPERIMENTAL
Intervention: Balanced protein intake (BAL: 25% daily protein/meal × 4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Skewed protein intake (SKEW: 7:17:72:4% daily protein/meal)
Number of subjects: 20
Study: 25076235

Group type: EXPERIMENTAL
Intervention: Thulium laser resection (group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mechanical staplers with or without sealants (group B)
Number of subjects: 72
Study: 22071248

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 39129

Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 39129
Study: 19620325

Group type: EXPERIMENTAL
Intervention: Sulfadoxine (SDOX) 1,500 mg plus pyrimethamine (PYR) 75 mg
Number of subjects: 60
Study: 17530985

Group type: EXPERIMENTAL
Intervention: 1-set strength training (n = 22)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3-set strength training (n = 22)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 39
Study: 15231376

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol 50 mg
Number of subjects: 23144

Group type: EXPERIMENTAL
Intervention: beta-carotene 20 mg
Number of subjects: 23144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23144
Study: 11199705

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with an energy of 140 mJ, a pulse repetition rate of 4 Hz (no water cooling)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nd:YAP laser with an energy of 240 mJ, a pulse repetition rate of 10 Hz (no water cooling)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-speed dental handpiece (no water cooling)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with an energy of 140 mJ, a pulse repetition rate of 4 Hz (with water spray)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nd:YAP laser with an energy of 240 mJ, a pulse repetition rate of 10 Hz (with water spray)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-speed dental handpiece (with water spray)
Number of subjects: 18
Study: 9049526

Group type: EXPERIMENTAL
Intervention: Quinaprilat (5 ml or 10 ml injection twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 0
Study: 8443480

Group type: EXPERIMENTAL
Intervention: Holding the infant 20 cm below the introitus for 30 seconds before clamping the umbilical cord (regulated group, 17 patients)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional management (random group, 19 patients)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Holding the infant 20 cm below the introitus for 30 seconds before clamping the umbilical cord (regulated group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional management (random group)
Number of subjects: 36
Study: 3533563

Group type: EXPERIMENTAL
Intervention: 200 mg ICI 141,292
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ICI 141,292 and atenolol
Number of subjects: 12
Study: 30844541

Group type: EXPERIMENTAL
Intervention: Intensive transitional care by a nurse‐led multidisciplinary team (MDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 0
Study: 28253390

Group type: EXPERIMENTAL
Intervention: TX+CEX (docetaxel plus capecitabine followed by cyclophosphamide, epirubicin, and capecitabine)
Number of subjects: 1495

Group type: COMPARATOR
Intervention: T+CEF (docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 1495
Study: 25338110

Group type: EXPERIMENTAL
Intervention: Porous titanium construct cup (n=25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional porous coated titanium cup (control group, n=26)
Number of subjects: 51
Study: 24482090

Group type: EXPERIMENTAL
Intervention: Turmeric
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21067273

Group type: EXPERIMENTAL
Intervention: Group LP: 20 mL of 0.25% levobupivacaine infiltration to the nephrostomy tract followed by intravenous paracetamol infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group SP: 20 mL saline infiltrated through the nephrostomy tract followed by intravenous paracetamol (4 × 1 g) infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group LS: 20 mL of 0.25% levobupivacaine infiltration to the nephrostomy tract followed by intravenous saline infusion
Number of subjects: 60
Study: 19910810

Group type: EXPERIMENTAL
Intervention: Basketball training (4-year systematic exercise program)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Occasional basketball participation (recreational)
Number of subjects: 24
Study: 17300593

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (100/30 mg q.d.)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (50/15 mg q.d.)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Pioglitazone 30 mg q.d. (monotherapy)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg q.d. (monotherapy)
Number of subjects: 607
Study: 15215794

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 11149474

Group type: EXPERIMENTAL
Intervention: Oral 10 mg alendronate on alternate days for 2 years
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral 10 mg alendronate
Number of subjects: 26
Study: 10401948

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) in low ventilation group (10 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation (ATC) in low ventilation group (10 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inspiratory Pressure Support (IPS) > 5 cm H2O in low ventilation group (10 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) in high ventilation group (> 10 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation (ATC) in high ventilation group (> 10 l/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inspiratory Pressure Support (IPS) in high ventilation group (> 10 l/min)
Number of subjects: 10
Study: 8583073

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg bolus and 40 mg/12 h i.v.)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ranitidine (50 mg/4 h i.v.)
Number of subjects: 51
Study: 2193242

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Sandoglobulin, Sandoz) 400 mg/kg, two times with an interval of two weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6996271

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bell and pad conditioning method
Number of subjects: 0
Study: 31833543

Group type: EXPERIMENTAL
Intervention: IVCS + Antibiotics (amoxicillin, vancomycin, metronidazole, doxycycline/ciprofloxacin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: IVCS only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IVCS + Antibiotics
Number of subjects: 28
Study: 30797222

Group type: EXPERIMENTAL
Intervention: Clonidine (25, 50, 75 or 150 μg, single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28492920

Group type: EXPERIMENTAL
Intervention: Intravitreous 0.5-mg ranibizumab therapy
Number of subjects: 305

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 305
Study: 25929985

Group type: EXPERIMENTAL
Intervention: Nurse assisted online cognitive‐behavioral self‐management intervention (DESTRESS‐PC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Optimized usual primary care PTSD Treatment (OUC)
Number of subjects: 80
Study: 23282858

Group type: EXPERIMENTAL
Intervention: CAT+ arm
Number of subjects: 165

Group type: COMPARATOR
Intervention: no CAT arm
Number of subjects: 165
Study: 21167682

Group type: EXPERIMENTAL
Intervention: Overnight fast
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich snack in the evening
Number of subjects: 39
Study: 18976267

Group type: EXPERIMENTAL
Intervention: KaVo Everest HPC crowns
Number of subjects: 224

Group type: COMPARATOR
Intervention: Gold crowns
Number of subjects: 224
Study: 17304146

Group type: EXPERIMENTAL
Intervention: Limited sampling strategy using two concentration measurements (0.5 and 6 hours or 0.5 and 8 hours after the end of infusion)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic parameters
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional method using five‐ to nine‐concentration data
Number of subjects: 51
Study: 12960682

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) at 0.5 microg/kg/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10756495

Group type: EXPERIMENTAL
Intervention: Methadone maintenance program (group 2)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Incarcerated women (group 1)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Incarcerated women (group 1) and methadone maintenance group (group 2)
Number of subjects: 149
Study: 8789548

Group type: EXPERIMENTAL
Intervention: Milk perfusion (10 mL at 3 mL/min) in patients with cow's milk intolerance
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 13
Study: 1362031

Group type: EXPERIMENTAL
Intervention: CLF vaccine (720 ELISA units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HM175 vaccine (1440 ELISA units, double dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HM175 vaccine (single dose at months 0 and 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HM175 vaccine (third dose)
Number of subjects: 0
Study: 6528959

Group type: EXPERIMENTAL
Intervention: Theo-Dur, 300 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Uniphylline, 600 mg once daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theo-Dur and Uniphylline
Number of subjects: 8
Study: 3453158

Group type: EXPERIMENTAL
Intervention: stepped‐up outreach rehabilitation program
Number of subjects: 57

Group type: COMPARATOR
Intervention: usual treatment
Number of subjects: 57
Study: 28278612

Group type: EXPERIMENTAL
Intervention: Complementary public service announcement after an organ donation story
Number of subjects: 310

Group type: COMPARATOR
Intervention: Viewing the same episode of the program on its own
Number of subjects: 310
Study: 27026689

Group type: EXPERIMENTAL
Intervention: Total power Doppler joint count ≤1 during a combined DAS28-ESR/MSUS assessment
Number of subjects: 111

Group type: COMPARATOR
Intervention: DAS28-erythrocyte sedimentation rate (ESR) <3.2
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intensive DMARD therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard DMARD therapy
Number of subjects: 111
Study: 23999998

Group type: EXPERIMENTAL
Intervention: High-dose oral cholecalciferol supplementation (140,000 IU/month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22882767

Group type: EXPERIMENTAL
Intervention: Single purse string with four-point traction (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single purse string with two-point traction (G1)
Number of subjects: 60